Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07225556 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 18, 2025
- Completion date
- December 31, 2026
- Enrollment
- 84 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.